title: Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
abstract: OBJECTIVE
  Insulin-like growth factor 1 (IGF-1) is an important mitogenic and antiapoptotic peptide that affects the proliferation of normal and malignant cells. Contradictory reports on the association between serum IGF-1 level and prostate cancer have been highlighted in the recent literature. The purpose of this study was to investigate the relation between serum levels of IGF-1 and prostate cancer.
  
  
  METHODS
  We analyzed a population of 57 patients who underwent radical prostatectomy (RP) for adenocarcinoma. Serum samples were collected before RP (T0), 6 months after RP (T6), and from 39 age-matched controls. IGF-1 levels were determined by the active IGF-1 Elisa kit (Diagnostic Systems Laboratories, Inc.). Parallel samples were evaluated for prostate-specific antigen (PSA) levels. Data between groups were analyzed using Welch's t-test and levels before RP and after 6 months were compared by paired t-test.
  
  
  RESULTS
  The normal mean serum IGF-1 for case patients at T0 (124.6+/-58.2 ng/mL) was significantly lower than the control subjects (157.5+/-70.8 ng/mL; p = .0192). The normal mean serum IGF-1 for case patients at T0 (124.91+/-58.6 ng/mL) also was significantly lower when it was compared with the T6 group (148.49+/-57.2 ng/mL; p = .0056). No association was found between IGF-1 and PSA blood levels, or IGF-1 and patient weight (p = 0.2434). An inverse relation between IGF-1 levels and age in the normal controls (p = .0041) was observed.
  
  
  CONCLUSIONS
  Findings of this study indicate a significant association between low serum levels of IGF-1 and prostate cancer.
authors.affiliation: Department of Urology, Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania 19107, USA.
authors.forename: R
authors.initials: R
authors.lastname: Baffa
authors.forename: K
authors.initials: K
authors.lastname: Reiss
authors.forename: E A
authors.initials: EA
authors.lastname: El-Gabry
authors.forename: J
authors.initials: J
authors.lastname: Sedor
authors.forename: M L
authors.initials: ML
authors.lastname: Moy
authors.forename: D
authors.initials: D
authors.lastname: Shupp-Byrne
authors.forename: S E
authors.initials: SE
authors.lastname: Strup
authors.forename: W W
authors.initials: WW
authors.lastname: Hauck
authors.forename: R
authors.initials: R
authors.lastname: Baserga
authors.forename: L G
authors.initials: LG
authors.lastname: Gomella
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011300:Preoperative Care; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D012016:Reference Values; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D007334:Insulin-Like Growth Factor I; D017430:Prostate-Specific Antigen